


IN THE CLAIMS:

Claim 1-6 (cancelled).

Claim 7 (currently amended): A compound of the formula B:



wherein:

X is O or H₂;

e is 0;

t is 1 to 4;

R^{2'}, R^{3'}, R^{4'}, and R^{5'} are independently selected from: H; C₁₋₈alkyl, alkenyl, alkynyl, aryl, heterocycle, -CO-NR^{6'}R^{7'} or -CO-OR^{6'}, unsubstituted or substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with:

a. C₁₋₄alkyl,

- b. $(\text{CH}_2)_t\text{OR}^{6'}$,
 - c. $(\text{CH}_2)_t\text{NR}^{6'}\text{R}^{7'}$,
 - d. halogen,
- 2) $\text{C}_{3-6}\text{cycloalkyl}$,
 - 3) $\text{OR}^{6'}$,
 - 4) $\text{SR}^{6'}$, $\text{S(O)R}^{6'}$, $\text{SO}_2\text{R}^{6'}$,
 - 5) $-\text{NR}^{6'}\text{R}^{7'}$,
 - 6) $-\text{NR}^{6'}-\text{CO}-\text{R}^{7'}$,
 - 7) $-\text{NR}^{6'}-\text{CO}-\text{NR}^{7'}\text{R}^{8'}$,
 - 8) $-\text{O}-\text{CO}-\text{NR}^{6'}\text{R}^{7'}$,
 - 9) $-\text{O}-\text{CO}-\text{OR}^{6'}$,
 - 10) $-\text{O}-\text{NR}^{6'}\text{R}^{7'}$,
 - 11) $-\text{SO}_2\text{NR}^{6'}\text{R}^{7'}$,
 - 12) $-\text{NR}^{6'}-\text{SO}_2-\text{R}^{7'}$,
 - 13) $-\text{CO}-\text{R}^{6'}$, or
 - 14) $-\text{CO}-\text{OR}^{6'}$;

and any two of $\text{R}^{2'}$, $\text{R}^{3'}$, $\text{R}^{4'}$, and $\text{R}^{5'}$ are optionally attached to the same carbon atom;

Y is aryl, heterocycle, unsubstituted or substituted with one or more of:

- 1) $\text{C}_{1-4}\text{alkyl}$, unsubstituted or substituted with:
 - a. $\text{C}_{1-4}\text{alkoxy}$,
 - b. $\text{NR}^{6'}\text{R}^{7'}$,
 - c. $\text{C}_{3-6}\text{cycloalkyl}$,
 - d. aryl or heterocycle,
 - e. HO ,
- 2) aryl or heterocycle,
- 3) halogen,
- 4) $\text{OR}^{6'}$,
- 5) $\text{NR}^{6'}\text{R}^{7'}$,
- 6) CN
- 7) NO_2 , or

8) CF₃;

R^{6'}, R^{7'} and R^{8'} are independently selected from: H; C₁₋₄alkyl, C₃₋₆cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with:

- a) C₁₋₄alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,
- e) -CO-R^{9'},
- f) -SO₂R^{9'}, wherein

R^{6'} and R^{7'} may be joined in a ring, and

R^{7'} and R^{8'} may be joined in a ring;

R^{9'} is C₁₋₄alkyl or aralkyl;


a pharmaceutically acceptable salt thereof.

Claim 8 (previously amended): The compound (2S)-2-(2-methoxy-ethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A pharmaceutical composition which comprises a compound according to ~~any one of claims 7 or 8~~ claim 7 or 8 and a pharmaceutically-acceptable carrier.

Claims 10-12 (cancelled).

Claim 13 (previously amended): A process for preparing compounds of the Formula B as defined in claim 7 which comprises deprotecting a compound of Formula VI:



Formula VI

wherein X^8 represents the right hand side of the Formula B as defined in claim 7, Pr^1 is H or an amino protecting group, Pr^2 is H or a thio protecting group and any functional groups in X^8 are optionally protected with the proviso that there is at least one protecting group and optionally, if desired, converting the product thus obtained into a pharmaceutically-acceptable salt thereof.

Claims 14-17 (cancelled).

Claim 18 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid or skin.

Claim 19 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a hematopoietic tumor of lymphoid lineage selected from acute lymphocytic leukaemia, B-cell lymphoma and Burketts lymphoma.

Claim 20 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8,

wherein said disease or medical condition is a hematopoietic tumor of myeloid lineage selected from acute or chronic myelogenous leukemias and promyelocytic leukaemia.

Claim 21 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma.

Claim 22 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor selected from melanoma, seminoma, teratocarcinoma, neuroblastoma and glioma.